// App-Quantinova.ai

32 : Sargramostim (GM-CSF) Combined with IV Plerixafor to Mobilize Peripheral Blood Stem Cells (PBSC) from Normal HLA-Matched Allogeneic Sibling Donors

Researchers

Presenter

  • Mark A. Schroeder

Principal Investigators

  • Sarah Merida

  • David Schwab

  • John F. DiPersio

  • Michael P. Rettig

  • Stephanie Meier

  • Sandra Lopez

  • Kathryn Trinkaus

  • Geoffrey L. Uy

  • Amanda Cashen

  • Keith Stockerl-Goldstein

  • Peter Westervelt

Medical Centers

  • Bone Marrow Transplantation & Leukemia Section, Division of Oncology, Washington University School of Medicine, St. Louis, MO

  • Division of Oncology, Washington University School of Medicine, St. Louis, MO

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Cytomegalovirus infection

  • Venous thrombosis

  • Graft-versus-host disease

Biomarkers

  • Cluster of Differentiation 34

  • Granulocyte-macrophage-colony stimulating factor

  • Regulatory T cells

Drug/Treatment

  • Sargramostim

  • Plerixafor

  • GM-CSF

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved